A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma
Latest Information Update: 26 Jul 2024
At a glance
- Drugs S 64315 (Primary) ; S 65487 (Primary)
- Indications Acute myeloid leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 23 Jul 2024 Planned End Date changed from 30 Jul 2024 to 26 Jul 2024.
- 23 Jul 2024 Planned primary completion date changed from 30 Jul 2024 to 26 Jul 2024.
- 13 May 2024 Planned End Date changed from 2 Aug 2024 to 30 Jul 2024.